National Health Investors, Inc. (NHI) Analyst Forecast
Revenue and earnings estimates published by analysts covering National Health Investors, Inc. (NHI), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For National Health Investors, Inc., analysts forecast revenue rising from $269.61T in 2025 to $307.67T in 2030; the average estimate for 2030 earnings per share is $0.00; 3 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD millions)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
National Health Investors, Inc. (NHI) forecast — frequently asked questions
What is the analyst price target for National Health Investors, Inc.?
Analysts covering National Health Investors, Inc. (NHI) have a consensus price target of $77.40, 15.1% above the current price of $67.22. Published targets range from $68.00 to $80.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for National Health Investors, Inc.'s earnings?
The average analyst estimate for National Health Investors, Inc. (NHI) earnings per share in 2030 is 0.00, with individual estimates between 0.00 and 0.00.
How much revenue is National Health Investors, Inc. expected to make?
Analysts forecast National Health Investors, Inc. (NHI) revenue of $307.67T in 2030, based on 2 published estimates.
How many analysts cover NHI?
3 analysts contribute estimates for National Health Investors, Inc. (NHI). Thin coverage makes an average less reliable.
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.